Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neptune Wellness Solutions Inc NEPTF

Neptune Wellness Solutions Inc. is a consumer-packaged goods company that is primarily focused on health and wellness products. The Company focuses on developing a portfolio of consumer products that align with the market trends for natural, sustainable, plant-based, and purpose-driven lifestyle brands. Its products are available in more than 29,000 retail locations and include organic food and beverage brands, such as Sprout Organics, Nosh, and Nurturme, as well as nutraceuticals brands like Biodroga and Forest Remedies. Its main brand units are nutraceuticals and organic foods and beverages. The Company sells its nutraceutical products mainly in bulk soft gels or liquids to multiple distributors and customers, who commercialize these products under their private label. The Company, through its Sprout subsidiary, sells its organic foods and beverages products to mass retailers, grocery stores and other retail outlets, as well as online through e-commerce sites and its own Website.


GREY:NEPTF - Post by User

Comment by dqmaon Nov 21, 2010 10:01am
354 Views
Post# 17735719

RE: Where's the AHA coverage?

RE: Where's the AHA coverage?the safety is still a question mark with anacetrapib, the merck drug that is closely associated with the failed pfizer drug torcetrapib.

https://www.bloomberg.com/news/2010-11-17/merck-drug-improves-cholesterol-without-safety-risk-of-pfizer-s-product.html


Torcetrapib increased the number of deaths in its finalstudy, making that a key issue, said Harlan Krumholz, acardiologist and professor at Yale University School ofMedicine. In Merck study today, four patients taking anacetrapiband one person given a placebo died from cardiovascular causes.While the difference could have stemmed from chance, it issomething to watch, he said.

“I’m not saying this will be a dangerous drug, but I’m notsure there will be reduction in deaths,” he said in aninterview. “I’m bullish on the idea of testing this, I’m justnot bullish about the result. I don’t have enough information.”


Bullboard Posts